share_log

Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Connect Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

康乃德生物 | 6-K：外國發行人報告（業績相關）
美股sec公告 ·  06/13 04:52
牛牛AI助理已提取核心訊息
Connect Biopharma Holdings Limited has announced significant changes in its executive leadership. On June 10, 2024, Zheng Wei, Ph.D., and Wubin Pan, Ph.D., communicated their intentions to resign from their respective roles as Chief Executive Officer and President of the company, effective June 12, 2024. Both executives are expected to continue serving in a transitional capacity post-resignation. Concurrently, the Board appointed Kleanthis G. Xanthopoulos, Ph.D., as the new Chairperson of the Board. Furthermore, Barry Quart, Pharm.D., with a notable background including leadership roles at Heron Therapeutics and Ardea Biosciences, has been appointed as the new CEO and a member of the Board. David Szekeres, with previous experience at Heron Therapeutics and Regulus Therapeutics, has been named the new President...Show More
Connect Biopharma Holdings Limited has announced significant changes in its executive leadership. On June 10, 2024, Zheng Wei, Ph.D., and Wubin Pan, Ph.D., communicated their intentions to resign from their respective roles as Chief Executive Officer and President of the company, effective June 12, 2024. Both executives are expected to continue serving in a transitional capacity post-resignation. Concurrently, the Board appointed Kleanthis G. Xanthopoulos, Ph.D., as the new Chairperson of the Board. Furthermore, Barry Quart, Pharm.D., with a notable background including leadership roles at Heron Therapeutics and Ardea Biosciences, has been appointed as the new CEO and a member of the Board. David Szekeres, with previous experience at Heron Therapeutics and Regulus Therapeutics, has been named the new President. These appointments coincide with the adoption of the 2024 Employment Inducement Incentive Award Plan, which is designed to provide incentives to new employees under Nasdaq rules. The plan initially reserves 4,500,000 shares for issuance under awards. The company has also entered into employment agreements with Dr. Quart and Mr. Szekeres, detailing their compensation, bonus eligibility, and severance terms.
Connect Biopharma Holdings Limited宣佈對其高管領導層進行了重大調整。2024年6月10日，鄭巍博士和Wubin Pan博士通知公司，他們將辭去各自的首席執行官和總裁職務，並於2024年6月12日生效。預計兩位高管將在辭職後繼續擔任過渡性職務。同時，董事會任命Kleanthis G. Xanthopoulos博士爲新任董事長。此外，Barry Quart藥劑學博士，曾擔任Heron Therapeutics和Ardea Biosciences的領導職務，已被任命爲該公司的新CEO和董事會成員。David Szekeres曾在Heron Therapeutics和...展開全部
Connect Biopharma Holdings Limited宣佈對其高管領導層進行了重大調整。2024年6月10日，鄭巍博士和Wubin Pan博士通知公司，他們將辭去各自的首席執行官和總裁職務，並於2024年6月12日生效。預計兩位高管將在辭職後繼續擔任過渡性職務。同時，董事會任命Kleanthis G. Xanthopoulos博士爲新任董事長。此外，Barry Quart藥劑學博士，曾擔任Heron Therapeutics和Ardea Biosciences的領導職務，已被任命爲該公司的新CEO和董事會成員。David Szekeres曾在Heron Therapeutics和Regulus Therapeutics擔任職務，現已被任命爲新的總裁。這些任命與採納2024年就業誘因激勵獎計劃同時進行，該計劃旨在根據納斯達克規定爲新員工提供激勵。該計劃最初爲獎項發行保留了4,500,000股。公司還與Quart博士和Szekeres先生簽訂了僱傭協議，詳細說明了他們的補償、獎金資格和遣散條款。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。